Clinical trials: Crohns Disease
Ulcerative Colitis, Crohn's Disease
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
- Trial name
- NCT01290042
- Testing
- AMG 181
- Where
- 8 sites in United States, Australia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Amgen
Crohn Disease, Arthritis, Rheumatoid
Remicade Infusion Management Program
Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate.
- Trial name
- RemiTRAC (NCT00723905)
- Where
- 2 sites in Canada
- Volunteers
- 1,630 people
- Sponsor
- Janssen Inc.
Crohn's Disease
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]).
- Trial name
- PRECiSE 3 (NCT00160524)
- Testing
- Certolizumab Pegol (CDP870)
- Where
- 206 sites in United States, Australia and 27 more
- Volunteers
- 596 people
- Sponsor
- UCB Pharma SA
Crohn's Disease
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and an ileostomy.
- Trial name
- CALLISTO (NCT06681324)
- Testing
- AZD7798
- Where
- 17 sites in Belgium, Italy and 5 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Crohn Disease
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease
This is a study of infliximab (Remicade) in subjects with Crohn's disease
- Trial name
- NCT00207662
- Volunteers
- 580 people
- Sponsor
- Centocor, Inc.
Colitis, Ulcerative, Crohn Disease
A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life
The purpose of this study is to describe in real life the effectiveness of treatment with vedolizumab.
- Conditions
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- GEVOL (NCT03378388)
- Where
- 13 sites in France
- Volunteers
- 29 people
- Sponsor
- Takeda
Crohn's Disease
Extension Study of MT-1303 in Subjects With Crohn's Disease
The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）
- Trial name
- NCT02389790
- Testing
- MT-1303
- Where
- 11 sites in Czechia, France and 9 more
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Inflammatory Bowel Diseases, Ulcerative Colitis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- Trial name
- CONNECT-IBD (NCT02539368)
- Testing
- CT-P13, Remicade
- Where
- 140 sites in Belgium, Czechia and 11 more
- Volunteers
- 2,565 people
- Sponsor
- Pfizer
Crohn's Disease
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment…
- Trial name
- COMPAS (NCT03559660)
- Testing
- Certolizumab Pegol
- Sponsor
- UCB Biopharma SRL
Crohn Disease
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response…
- Trial name
- POWER (NCT03782376)
- Testing
- Ustekinumab approximately 6 mg/kg (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 215 people
- Sponsor
- Janssen-Cilag Ltd.
Crohn Disease
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe…
- Trial name
- NCT03905109
- Testing
- ABX464
- Where
- Belgium
- Sponsor
- Abivax S.A.
Crohn Disease
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.
- Trial name
- NCT00354367
- Testing
- Certolizumab pegol
- Sponsor
- UCB Pharma
Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA)
A Real-world Study of Imraldi® Use
The primary objective of this study is to evaluate candidate predictors of persistence on adalimumab (Imraldi®) participants diagnosed with immune-mediated inflammatory disease in Europe (EU).
- Conditions
- Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA), Arthritis, Psoriatic (PsA), Crohn's Disease (CD)
- Trial name
- PROPER (NCT04089514)
- Testing
- Adalimumab
- Where
- 54 sites in Belgium, Germany and 4 more
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Crohn's Disease
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059…
- Trial name
- COSPAR II (NCT00356408)
- Testing
- Certolizumab pegol
- Where
- 63 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- UCB Pharma
Crohn's Disease
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
- Trial name
- NCT00584740
- Testing
- AIN457
- Where
- 2 sites in Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Crohn Disease
A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from…
- Trial name
- EBFIM117 (NCT03709628)
- Testing
- EB8018 (First-in-class FimH blocker)
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 8 people
- Sponsor
- Enterome
Crohn's Disease
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
The purpose of this study is to determine the safety and tolerability of natalizumab in adolescents (ages 12-17) diagnosed with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT00055367
- Testing
- natalizumab
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Biogen
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis
In this study, participants with ulcerative colitis or Crohn's disease or pouchitis will be treated with Kynteles injection (Vedolizumab) according to their clinic's standard practice.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT04799496
- Where
- 43 sites in South Korea
- Volunteers
- 688 people
- Sponsor
- Takeda
Crohn's Disease
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD).
- Trial name
- ENCORE (NCT00705614)
- Testing
- Remicade
- Volunteers
- 2,662 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels.
- Trial name
- U-EMPOWER (NCT06332534)
- Testing
- Upadacitinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 111 people
- Sponsor
- AbbVie